

LIST OF PUBLICATIONS

* Equal contribution

1. Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera A, D'Amore ML, Di Cecca S, Sinibaldi M, Guercio M, Aurigemma M, De Falco P, Fustaino V, Rota R, **Pomella S**, Cassandri M, Di Giannatale A, Agrati C, Bordoni V, Guarracino F, Massa M, Del Baldo G, Becilli M, Milano GM, Del Bufalo F, Locatelli F, De Angelis B. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. *J Hematol Oncol.* **2024.**
2. **Pomella S**, Melaiu O, Cifaldi L, Bei R, Gargari M, Campanella V, Barillari G. Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies. *Int J Mol Sci.* **2024.**
3. **Pomella S**, Melaiu O, Dri M, Martelli M, Gargari M, Barillari G. Effects of Angiogenic Factors on the Epithelial-to-Mesenchymal Transition and Their Impact on the Onset and Progression of Oral Squamous Cell Carcinoma: An Overview. *Cells.* **2024.**
4. Cassandri M*, Porrazzo A*, **Pomella S***, Noce B, Zwergel C, Aiello F, Vulcano F, Milazzo L, Camero S, Pajalunga D, Spada M, Manzi V, Gravina G, Codenotti S, Piccione M, Tomaciello M, Signore M, Barillari G, Marchese C, Fanzani A, De Angelis B, Quintarelli C, Vakoc C, Chen E, Megiorni F, Locatelli F, Valente S, Mai A, Rota R, Marampon F. HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks. Accepted. *Cell Death Discov.* **2024.**
5. Camero S, Milazzo L, Vulcano F, Ceccarelli F, Pontecorvi P, Pedini F, Rossetti A, Scialis ES, Gerini G, Cece F, **Pomella S**, Cassandri M, Porrazzo A, Romano E, Festuccia C, Gravina GL, Ceccarelli S, Rota R, Lotti LV, Midulla F, Angeloni A, Marchese C, Marampon F, Megiorni F. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma. *BMC Cancer.* **2024.**
6. Stanton BZ, **Pomella S**. Epigenetic determinants of fusion-driven sarcomas: paradigm and challenges. *Front Cell Dev Biol.* **2024.**
7. Ciani L, Libonati A, Dri M, **Pomella S**, Campanella V, Barillari G. Abot a possible impact of endodontic infections by *Fusobacterium nucleatum* or *Porphyromonas gingivalis* on oral carcinogenesis: a literature overview. *Int. J. Mol. Sci.* **2024.**
8. Kim YY, Gryder BE, Sinniah R, Peach ML, Shern JF, Abdelmaksoud A, **Pomella S**, Woldemichael GM, Stanton BZ, Milewski D, Barchi JJ, Schneekloth JS, Chari R, Kowalczyk JT, Shenoy SR, Evans JR, Song YK, Wang C, Wen X, Chou HC, Gangalapudi V, Esposito D, Jones J, Procter L, O'Neill M, Jenkins LM, Tarasova NI, Wei JS, McMahan JB, O'Keefe BR, Hawley RG, Khan J. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma. *Nat Commun.* **2024.**

9. **Pomella S**, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting. *Nat Commun.* **2023**.
10. **Pomella S**, Danielli SG, Alaggio R, Breunis WB, Hamed E, Selfe J, Wachtel M, Walters ZS, Schäfer BW, Rota R, Shipley JM, Hettmer S. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma. *Cancers.* **2023**.
11. **Pomella S***, Cassandri M*, Melaiu O, Marampon F, Gargari M, Campanella V, Rota R, Barillari G. DNA Damage Response Gene Signature as Potential Treatment Markers for Oral Squamous Cell Carcinoma. *Int. J. Mol. Sci.* **2023**.
12. Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, **Pomella S**, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. The combination of immune checkpoint blockade with tumor vessel normalization as a promising therapeutic strategy for breast cancer: an overview of preclinical and clinical studies. *Int. J. Mol. Sci.* **2023**.
13. Perrone C*, **Pomella S***, Cassandri M*, Pezzella M, Giuliani S, Gasperi T, Porrazzo A, Alisi A, Pastore A, Codenotti S, Fanzani A, Barillari G, Conti LA, De Angelis B, Quintarelli C, Mariottini P, Locatelli F, Marampon F, Rota R, Cervelli M. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation. *Front. Cell Dev. Biol.* **2023**.
14. Vaccaro S, Rossetti A, Porrazzo A, Camero S, Cassandri M, **Pomella S**, Tomaciello M, Macioce G, Pedini F, Barillari G, Marchese C, Rota R, Cenci G, Tombolini M, Newman RA, Yang P, Codenotti S, Fanzani A, Megiorni F, Festuccia C, Minniti G, Gravina GL, Vulcano F, Milazzo L, Marampon F. The botanical drug PBI-05204, a supercritical CO₂ extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. *Front. Pharmacol.* **2022**.
15. **Pomella S***, Porrazzo A*, Cassandri M, Camero S, Codenotti S, Milazzo L, Vulcano F, Barillari G, Cenci G, Marchese C, Fanzani A, Megiorni F, Rota R, Marampon F. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. *Int. J. Mol. Sci.* **2022**.
16. Camero S*, Cassandri M*, **Pomella S***, Milazzo L, Vulcano F, Porrazzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Radioresistance in rhabdomyosarcomas: Much more than a question of dose. *Front. Oncol.* **2022**.
17. Barillari G, Melaiu O, Gargari M, **Pomella S**, Bei R, Campanella V. The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview. *Int. J. Mol. Sci.* **2022**.

18. Menna M, Fiorentino F, Marrocco B, Lucidi A, Tomassi S, Cilli D, Romanenghi M, Cassandri M, **Pomella S**, Pezzella M, Del Bufalo D, Zeya Ansari MS, Tomašević N, Mladenović M, Viviano M, Sbardella G, Rota R, Trisciuglio D, Minucci S, Mattevi A, Rotili D, Mai A. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. *Eur J Med Chem.* **2022**.
19. Perrone C*, **Pomella S***, Cassandri M*, Pezzella M, Milano GM, Colletti M, Cossetti C, Pericoli G, Di Giannatale A, de Billy E, Vinci M, Petrini S, Marampon F, Quintarelli C, Tauli R, Roma J, Gallego S, Camero S, Mariottini P, Cervelli M, Maestro R, Miele L, De Angelis B, Locatelli F, Rota R. MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. *Front. Oncol.* **2022**.
20. Braghini MR, Lo Re O, Romito I, Fernandez-Barrena MG, Barbaro B, **Pomella S**, Rota R, Vinciguerra M, Avila MA, Alisi A. Epigenetic remodelling in human hepatocellular carcinoma. *J Exp Clinical Cancer Research.* **2022**.
21. **Pomella S**, Cassandri M, Braghini MR, Marampon F, Alisi A, Rota R. New Insights on the Nuclear Functions and Targeting of FAK in Cancer. *Int. J. Mol. Sci.* **2022**.
22. Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, **Pomella S**, Levi Mortera S, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. *J Exp Clinical Cancer Research.* **2021**.
23. Camero S, Vitali G, Pontecorvi P, Ceccarelli S, Anastasiadou E, Cicchetti F, Flex E, **Pomella S**, Cassandri M, Rota R, Marampon F, Marchese C, Schiavetti A, Megiorni F. DNMT3A and DNMT3B targeting as an effective radiosensitizing strategy in embryonal rhabdomyosarcoma. *Cells.* **2021**.
24. Cassandri M*, **Pomella S***, Rossetti A*, Petragnano F*, Milazzo L, Vulcano F, Camero S, Codenotti S, Cicchetti F, Maggio R, Festuccia C, Gravina GL, Fanzani A, Megiorni F, Catanoso M, Marchese C, Tombolini V, Locatelli F, Rota R, Marampon F. MS- 275 (Entinostat) Promotes Radio-sensitivity in PAX3-FOXO1 Rhabdomyosarcoma cells. *Int. J. Mol. Sci.* **2021**.
25. Wang L, Hensch NR, Bondra K, Sreenivas P, Zhao XR, Chen J, Moreno Campos R, Baxi K, Vaseva AV, Sunkel BD, Gryder BE, **Pomella S**, Stanton BZ, Zheng S, Chen EY, Rota R, Khan J, Houghton PJ, Ignatius MS. SNAI2-mediated repression of BIM protects rhabdomyosarcoma from ionizing radiation. *Cancer Res.* **2021**.
26. Rossetti A, Petragnano F, Milazzo L, Vulcano F, Macioce G, Codenotti S, Cassandri M, **Pomella S**, Cicchetti F, Fasciani I, Antinozzi C, Di Luigi L, Festuccia C, De Felice F, Vergine M, Fanzani A, Rota R, Maggio R, Polimeni A, Tombolini V, Gravina GI, Marampon F. Romidepsin (FK228) Fails In Counteracting The Transformed Phenotype Of Rhabdomyosarcoma Cells But Efficiently Radiosensitizes, In Vitro And In Vivo, The Alveolar Phenotype Subtype. *Int J Radiat Biol.* **2021**.
27. Tiago T, Hummel B, Morelli FF, Basile V, Vinet J, Galli V, Mediani L, Antoniani F, **Pomella S**, Cassandri M, Garone MG, Silvestri B, Cimino M, Cenacchi G, Costa R, Mouly V, Poser I, Yeger-Lotem

- E, Rosa A, Alberti S, Rota R, Ben-Zvi A, Sawarkar R, Carra S. Small Heat-Shock Protein Hspb3 Promotes Myogenesis By Regulating the Lamin B Receptor. *Cell Death Dis.* **2021**.
28. **Pomella S***, Sreenivas P*, Gryder BE*, Wang L, Cassandri M, Baxi K, Hensch NR, Carcarino E, Song Y, Yohe ME, Stanton BZ, Amadio B, Caruana I, De Stefanis C, De Vito, Locatelli F, Chen Y, Chen EY, Houghton P, Khan J, Rota R, Ignatius MS. Interaction Between SNAI2 And MYOD Enhances Oncogenesis and Suppresses Differentiation In Fusion-Negative Rhabdomyosarcoma. *Nat Commun.* **2021**.
29. Perrone C*, **Pomella S***, Cassandri M*, Braghini Mr, Pezzella M, Locatelli F, Rota R. Fak Signaling In Rhabdomyosarcoma. *Int. J. Mol. Sci.* **2020**.
30. Cassandri M, Fioravanti R, **Pomella S**, Valente S, Rotili D, Del Baldo G, De Angelis B, Rota R, Mai A. CDK9 As A Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. *Front. Pharmacol.* **2020**.
31. Gryder BE, Wachtel M, Chang K, El Demerdash O, Aborenden NA, Mohammed W, Ewert W, **Pomella S**, Rota R, Wei JS, Song Y, Stanton BZ, Schäfer B, Vakoc CR, Khan J. Miswired Enhancer Logic Drives A Cancer of The Muscle Lineage. *IScience.* **2020**.
32. Romanelli A, Stazi G, Fioravanti R, Zwergel C, Di Bello E, **Pomella S**, Perrone C, Battistelli C, Strippoli R, Tripodi M, Del Bufalo D, Rota R, Trisciuglio D, Mai A, Valente S. Design of First-In-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity And Biological Evaluation In Cancer Cells. *ACS Med Chem Lett.* **2020**.
33. Pomella S, Rota R. The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas. *Front. Chem.* **2020**.
34. Chiarella AM, Butler KV, Gryder BE, Lu D, Wang TA, Yu X, **Pomella S**, Khan J, Jin J, Hathaway NA. Dose-Dependent Activation of Gene Expression Is Achieved Using CRISPR And Small Molecules That Recruit Endogenous Chromatin Machinery. *Nature Biotechnol.* **2020**.
35. Gryder BE, **Pomella S**, Sayers C, Wu XS, Song Y, Chiarella AM, Bagchi S, Chou HC, Sinniah RS, Walton A, Wen X, Rota R, Hathaway NA, Zhao K, Chen J, Vakoc CR, Shern JF, Stanton BZ, Khan J. Histone Hyperacetylation Disrupts Core Gene Regulatory Architecture in Rhabdomyosarcoma. *Nature Genet.* **2019**.
36. Gryder BE, Wu L, Woldemichael GM, **Pomella S**, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, Wiest O, Yohe ME, Shern JF, Qi J, Khan J. Chemical Genomics Reveals Histone Deacetylases Are Required for Core Regulatory Transcription. *Nature Commun.* **2019**.
37. Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song YK, Gualtieri A, **Pomella S**, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J. Pax3-Foxo1 Establishes Myogenic Super Enhancers and Confers Bet Bromodomain Vulnerability. *Cancer Discov.* **2017**.
38. Iacobucci I, Ghelli Luserna Di Rorà A, Verga Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, **Pomella S**, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante M, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. In

Vitro And In Vivo Single-Agent Efficacy Of Checkpoint Kinase Inhibition In Acute Lymphoblastic Leukemia. *J Hematol. Oncol.* **2015.**

39. Vella S*, **Pomella S***, Leoncini P P, Coletti M, Conti B, Marquez V E, Strillacci A, Roma J, Gallego S, Milano G M, Capogrossi M C, Bertaina A, Ciarapica R, Rota R. MicroRNA-101 Is Repressed By Ezh2 And Its Restoration Inhibits Tumorigenic Features In Embryonal Rhabdomyosarcoma. *Clin. Epigenetics.* **2015.**